Taysha Gene Therapies, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-109.0M | $-89.3M | $-111.6M | $-166.0M | $-174.5M | $-60.0M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $1.1M | $1.2M | $1.4M | $1.2M | $492.0K | $9.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $13.3M | $13.1M | $7.9M | $18.0M | $18.2M | $3.4M |
| Net Cash from Operating Activities | $-93.1M | $-81.2M | $-73.0M | $-88.4M | $-117.0M | $-30.7M |
| Investing Activities | ||||||
| Capital Expenditures | $738.0K | $374.0K | $3.9M | $20.6M | $15.3M | $82.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-604.0K | $-363.0K | $-7.4M | $-24.9M | $-21.6M | $-9.1M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $274.6M | $76.7M | $136.4M | $52.1M | $39.1M | $291.1M |
| Net Change in Cash | $180.9M | $-4.9M | $56.0M | $-61.2M | $-99.5M | $251.3M |
| Free Cash Flow | $-93.8M | $-81.6M | $-76.9M | $-109.0M | $-132.3M | $-30.8M |